AbbVie Completes $1.4B Acquisition of Aliada Therapeutics

Eli Lilly & Company Acquires CrossBridge Bio

April 14, 2026

Biotechnology

Eli Lilly and Company has entered into a definitive agreement to acquire CrossBridge Bio, a Houston-based pre-clinical biotechnology company developing next-generation dual-payload antibody-drug conjugates (ADCs). The deal provides for up to $300 million in total consideration, including upfront and milestone-based payments, to advance CrossBridge Bio’s TROP2-targeting TOP1i/ATRi ADC platform led by CBB-120.

Lunai Bioworks Acquires BBB Delivery Technology and CNS Alzheimer’s Drug Assets from the Clemann Group

March 26, 2026

Biotechnology

Lunai Bioworks executed a binding $20 million strategic transaction to acquire blood-brain barrier (BBB) delivery technology and CNS Alzheimer’s drug assets from the Clemann Group, SAS (or its assignee). The deal is structured as Series B Convertible Preferred with a fixed $1.50 conversion price and is intended to strengthen Lunai’s CNS Alzheimer's pipeline while enabling development across other CNS disorders.

Biogen Acquires Alcyone Therapeutics

September 19, 2025

Medical Devices

Biogen has acquired Alcyone Therapeutics to obtain the ThecaFlex DRx intrathecal drug‑delivery system, integrating Alcyone employees into Biogen’s product delivery solutions team. Alcyone will receive $85 million upfront plus contingent milestone payments; Biogen will handle development, commercialization and manufacturing of ThecaFlex DRx while Alcyone’s remaining therapeutic assets are being divested into Neela Therapeutics.

Brookfield Asset Management and CDPQ Acquire Antylia Scientific from GTCR

May 28, 2025

Medical Devices

Brookfield Asset Management's private equity business, together with Brookfield Business Partners and CDPQ, completed the acquisition of Antylia Scientific from GTCR for approximately $1.3–$1.34 billion. Antylia, headquartered in Vernon Hills, Illinois, is a diversified life‑sciences tools manufacturer and distributor serving biopharma, clinical diagnostics and environmental testing markets; the transaction represents a PE exit after a decade of GTCR partnership and transformational growth.

AbbVie Acquires Nimble Therapeutics in $200 Million Deal

January 23, 2025

Biotechnology

AbbVie announced and later completed the acquisition of Nimble Therapeutics for $200 million in cash at closing, plus interim funding and potential development milestone payments to Nimble shareholders. The deal adds Nimble’s preclinical oral peptide IL23R inhibitor for psoriasis/IBD and its proprietary peptide synthesis, screening, and optimization platform to strengthen AbbVie’s immunology pipeline and R&D capabilities.

AbbVie Acquires Syndesi Therapeutics

March 1, 2022

Biotechnology

AbbVie has acquired Syndesi Therapeutics for up to US$1.0 billion, including US$130 million upfront, to strengthen its neuroscience portfolio and accelerate Syndesi's lead SV2A program SDI-118 into later-stage development. Syndesi was a Novo Seeds / UCB spin-out backed by Novo Holdings and a syndicate of Belgian and international investors.